New autism medication trial aims to ease social challenges

NCT ID NCT05081245

Ongoing Symptom relief Sponsor: MapLight Therapeutics Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an investigational medication called ML-004 can help improve social communication difficulties in adolescents and adults with autism spectrum disorder (ASD). Approximately 150 participants will be randomly assigned to receive either ML-004 or a placebo (inactive pill) for comparison. The main goal is to see if the medication reduces core autism symptoms related to social interaction and communication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

APG Research, LLC

Orlando, Florida, 32803, United States
Abba Medical Group

Miami, Florida, 33176, United States
BioBehavioral Research of Austin

Austin, Texas, 78759, United States
Brain and Mind Centre

Camperdown, New South Wales, 2050, Australia
Cedar Clinical Research

Draper, Utah, 84020, United States
Center for Autism and the Developing Brain, New York State Psychiatric Institute

White Plains, New York, 10605, United States
Children's National Health System - The Children's Research Institute (CRI)

Washington D.C., District of Columbia, 20010, United States
Cortica

San Rafael, California, 94903, United States
Cortica Healthcare

Glendale, California, 91203, United States
Family Psychiatry of The Woodlands

The Woodlands, Texas, 77381, United States
Harmonex Neuroscience Research

Dothan, Alabama, 36303, United States
Holland Bloorview Kids Rehabilitation Hospital

Toronto, Ontario, M4G 1R8, Canada
Jersey Shore University Medical Center

Neptune City, New Jersey, 07753, United States
Lawson Health Research Institute/ London Health Sciences Centre

London, Ontario, N6A 5W9, Canada
NRC Research Institute

Orange, California, 92868, United States
Nathan Kline Institute for Psychiatric Research

Orangeburg, New York, 10962, United States
Neurobehavioral Medicine Group

Bloomfield Hills, Michigan, 48302, United States
OCT Research ULC (dba Okanagan Clinical Trials)

Kelowna, British Columbia, V1Y 1Z9, Canada
Ohio State University Nisonger Center

Columbus, Ohio, 43210, United States
Red Oak Psychiatry Associates, PA

Houston, Texas, 77090, United States
Richmond Behavioral Associates

Staten Island, New York, 10314, United States
Road Runner Research, Ltd.

San Antonio, Texas, 78249, United States
Southwest Autism Research & Resource Center, Clinical Research

Phoenix, Arizona, 85006, United States
Suburban Research Associates

Media, Pennsylvania, 19063, United States
The Royal Children's Hospital, Murdoch Children's Research Institute

Parkville, Victoria, 3052, Australia
University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders

Columbia, Missouri, 65211, United States
University of South Florida Psychiatry and Behavioral Neurosciences

Tampa, Florida, 33613, United States
Virginia Commonwealth University

Richmond, Virginia, 23220, United States
Yale Child Study Center

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

AUTISM SPECTRUM DISORDER